The oncology pipeline has never been more promising, or more operationally demanding.
Across the life sciences industry, precision medicine, antibody-drug conjugates (ADCs), cell and gene therapies, and biomarker-driven research are reshaping how oncology programs are developed. Clinical teams are designing more targeted studies, working with increasingly specialized patient populations, and incorporating new sources of evidence throughout the development lifecycle.
That progress has fundamentally changed the role of Clinical Operations.
Pharmaceutical and biotech organizations have advanced their science rapidly – but their operating models have not kept pace. Teams still rely on disconnected systems, manual handoffs, and point solutions that support individual functions but rarely support study execution end to end. Patients wait. Timelines slip. Revenue is at risk.
As oncology programs become more adaptive and data-intensive, Clinical Operations has become one of the biggest determinants of study execution. Process Automation has helped organizations bring structure and consistency to these workflows. AI now creates an opportunity to take that capability further by bringing interpretation, prediction, and decision-making into the processes themselves.
Why Clinical Operations Need a New Operating Model
Oncology research has become significantly more interconnected over the last decade. Adaptive protocols, biomarker-driven recruitment, real-world evidence, and increasingly specialized data have expanded the number of decisions and dependencies involved in every study.
As work moves across teams and systems, manual coordination often fills the gaps. Clinical Operations teams spend valuable time tracking approvals, following up on dependencies, and reconciling information from multiple sources to keep studies moving. At the same time, R&D IT teams face the growing challenge of integrating an expanding technology landscape without disrupting ongoing operations. The result is an operating model where sophisticated clinical programs are supported by workflows that remain fragmented.
Where Fragmentation Impacts Clinical Operations
The effects of fragmented operations are rarely confined to a single department. They become most visible where work moves between teams, systems, and organizations. Three areas illustrate this particularly well.
Study Start-Up
Few phases of a clinical trial demand more coordination than Study Start-Up. Protocol reviews, site feasibility, investigator selection, ethics approvals, contracts, budgets, and country-specific regulatory requirements often progress simultaneously, with each activity depending on several others.
For Clinical Operations teams, maintaining visibility across these moving parts can be more challenging than completing the individual tasks themselves. A delayed contract can postpone site activation. A protocol amendment can trigger document revisions across multiple stakeholders. An unresolved dependency in one region can affect first-patient-in timelines across the broader program.
The sources of delay are often highly operational. A 2025 WCG survey cited in a recent clinical trial start-up analysis found that 72% of sites identified budget negotiations and 60% identified contract finalization among the top causes of start-up delays. These activities involve multiple stakeholders, rounds of review, approvals, and follow-ups, making them particularly susceptible to coordination gaps.
AI-enabled automation can help reduce some of this coordination burden. AI can extract information from study and regulatory documents, identify missing or inconsistent information, summarize requirements, and flag activities that require attention. Process Automation then connects these capabilities to the broader workflow, routing tasks, managing approvals, monitoring dependencies, and escalating exceptions.
Real-World Evidence
Real-world evidence is no longer limited to post-market studies. It increasingly informs protocol design, patient identification, biomarker validation, comparative effectiveness studies, and regulatory decision-making throughout oncology development.
Most organizations already have access to valuable data through registries, electronic health records, published literature, genomic repositories, and external partners.
Evidence often needs to be extracted, validated, consolidated, and shared manually before it can support study planning. By the time it reaches the teams responsible for operational decisions, opportunities to refine recruitment strategies or improve study design may already have passed.
AI can help change this by extracting and synthesizing relevant information from large volumes of structured and unstructured data, identifying patterns, and surfacing evidence that may be relevant to study planning. When these capabilities are embedded within automated workflows, insights can move more directly into the processes where clinical teams need to review and act on them.
Study Data Access Management
Modern oncology programs generate enormous volumes of information across clinical trial systems, laboratory platforms, imaging repositories, genomic databases, wearable devices, and real-world data sources.
The difficulty lies in making that information available when it is needed.
Researchers request access from multiple systems. Data managers validate different versions of the same dataset. Operational teams spend time reconciling information before they can act on it. As more data becomes available, the effort required to locate and trust that data often increases as well.
AI can assist by classifying access requests, identifying the data and permissions involved, checking submissions for completeness, and helping determine the appropriate next step. Process Automation can then manage approvals, route requests, monitor SLAs, and maintain an auditable record of activity.
Although these three areas serve different purposes, they reveal the same underlying issue. Clinical execution continues to rely on processes that span disconnected systems, fragmented data, and manual coordination.
The Case for Process Automation in Clinical Operations
Next-generation oncology programs require workflows that connect people, applications, and decisions across the entire study lifecycle. Activities should move seamlessly from one stakeholder to the next, dependencies should be visible before they become delays, and operational teams should be able to manage the program as a connected whole rather than a collection of individual tasks.
This is where Process Automation plays a fundamentally different role.
Rather than replacing existing systems, it provides the operational framework that connects them. Routine activities are automated, approvals move through standardized workflows, dependencies are monitored continuously, and teams gain visibility into how work progresses across functions.
AI extends what those automated workflows can do.
Traditional automation works well when the rules are known and the sequence of activities is predictable. Clinical development frequently involves situations that require interpretation. A document may contain missing information. A protocol amendment may affect several downstream activities. A site may be falling behind for reasons that are not immediately apparent from its task status.
AI-enabled automation can interpret information and respond to context rather than simply follow a predefined sequence. It can classify documents, extract relevant information, compare content, identify exceptions, summarize findings, and recommend the appropriate next step.
Process Automation then provides the mechanism to act on those insights within the workflow.
The potential impact of improving these processes can be substantial. One study cited in a recent clinical trial start-up analysis found that introducing a process intervention reduced mean start-up cycle time from approximately 24.8 weeks to 13.5 weeks-a 45.6% reduction. While this was a study-specific result rather than an industry-wide benchmark, it illustrates how better process design and coordination can materially compress operational timelines.
Connected Clinical Operations Need Connected Data
AI-enabled automation depends on more than the AI model itself. The intelligence needs access to the information required to understand the process and make an informed recommendation.
Clinical operations today depend on data distributed across clinical trial management systems, electronic trial master files, laboratory platforms, regulatory repositories, electronic health records, imaging systems, genomic databases, and external evidence sources.
A Data Fabric creates a unified information layer across the existing technology landscape, allowing data to move securely between systems without extensive point-to-point integrations. Operational teams gain access to trusted information regardless of where it originates, enabling decisions based on a complete picture rather than fragmented reports.
This connected data also gives AI the context it needs to operate effectively.
An AI Agent monitoring Study Start-Up, for example, can consider document status, site information, approvals, milestones, and historical activity rather than looking at a single task in isolation. An Agent supporting RWE workflows can draw on multiple sources of evidence. An Agent managing data access can consider the request, the dataset, the user’s role, and the relevant approval requirements.
The impact is felt across the clinical lifecycle. Site feasibility can incorporate richer operational and patient insights. Study teams can access real-world evidence without lengthy manual consolidation. Researchers spend less time searching for information, while Clinical Operations gains earlier visibility into issues that could affect execution.
How Agentic AI Makes Clinical Operations More Intelligent
AI-enabled automation can interpret information and support decisions within individual workflows. Agentic AI takes this further by allowing AI systems to monitor the broader state of a process, reason about what is happening, and initiate appropriate actions within defined parameters.
AI Agents work most effectively when they understand both the process and the context in which work is happening. That context comes from standardized workflows and connected data.
The potential for this shift is significant. McKinsey’s analysis of 270 life sciences workflows and more than 1,200 tasks found that 75-85% of pharma workflows contain tasks that could be augmented or automated by agents, with the potential to free up 25-40% of organizational capacity.
The opportunity is particularly relevant to clinical development. McKinsey estimates that agentic AI could deliver a 35-45% productivity boost across clinical development over the next five years. Within that, clinical operations and trial management could see time savings equivalent to approximately 35-40% of function capacity.
Agentic AI works most effectively as a participant in the operational ecosystem – not as a standalone assistant.
They monitor milestone progress, flag SLA risks before they affect timelines, generate regulatory document summaries, coordinate approval follow-ups across stakeholders, and surface biomarker and operational insights when study teams need them.
Importantly, they do not replace the expertise of Clinical Operations or R&D teams. They augment it by reducing the effort required to monitor increasingly complex programs and allowing teams to focus on higher-value decisions. AI gains the context needed to improve the operation as a whole.
Operational Excellence Is Now a Competitive Differentiator in Oncology
Scientific innovation will continue to define the future of oncology. Operational excellence will increasingly determine how quickly that innovation reaches patients.
As clinical programs become more specialized, organizations will need operating models that are designed for coordination rather than manual intervention. That means thinking beyond individual technologies and focusing on how work moves across the clinical ecosystem.
Process Automation provides the operational backbone that orchestrates people, processes, and systems.
Data Fabric ensures the right information is available wherever decisions need to be made.
Agentic AI builds on both, helping organizations anticipate risks, accelerate decisions, and continuously improve execution.
Together, they create an operating model built for the speed, complexity, and scale that next-generation oncology programs demand. See how Princeton Blue has built this for life sciences clients – and what it takes to get there.
